02. November 2008
Meet Zedira at MEDICA in November 2008

01. November 2008
Meet Zedira at BIO-Europe in November 2008

03. September 2008
Sanofi-Aventis names Zedira as supplier for R&D products in September 2008

02. September 2008
Structure of inhibited tissue transglutaminase published at XXth International Symposium on Medicinal Chemistry in September 2008

02. September 2008
What Links Celiac Disease, Thrombosis, Skin and Hair? (Article in lab&more September 2008)

08. August 2008
Novo Nordisk names Zedira as supplier for R&D products in August 2008

03. June 2008
Zedira launches TG6 In Vitro Diagnostic (IVD) in June 2008

01. April 2008
Transglutaminase Newsletter April 2008


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 8th Annual World ADC

    26.03.2018 - 28.03.2018
    Berlin, Germany

  • 25th International Fibrinogen & Factor XIII Workshop

    03.06.2018 - 07.06.2018
    Wake Forest University in Winston-Salem, NC (USA)

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland